Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral esketamine versus ECT for non-psychotic treatment-resistant depression
NL-OMON51415Phase 3Not yet recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of esketamine in treatment-resistant depression (TRD) (2 arms), sponsored by University Medical Center Groningen. Primary endpoint: Primary: response at 8 weeks by MADRS. Planned start Feb 2022; status: not yet recruiting.
02
Drugs
esketamine
03
Conditions
treatment-resistant depression (TRD)
Beyond the preview
Go deeper on NL-OMON51415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51415.